Comparative Pharmacology
Head-to-head clinical analysis: ALLOPURINOL versus ZYLOPRIM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALLOPURINOL versus ZYLOPRIM.
ALLOPURINOL vs ZYLOPRIM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Allopurinol inhibits xanthine oxidase, the enzyme responsible for the conversion of hypoxanthine to xanthine and xanthine to uric acid, thereby reducing serum and urinary uric acid concentrations. It also inhibits de novo purine synthesis through feedback inhibition.
Allopurinol is a xanthine oxidase inhibitor that reduces the production of uric acid by inhibiting the conversion of hypoxanthine to xanthine and xanthine to uric acid.
100-600 mg orally once daily; initial 100 mg/day with weekly increases of 100 mg/day; maximum 800 mg/day.
100-300 mg orally once daily, maximum 800 mg/day.
None Documented
None Documented
Allopurinol: 1–2 hours; oxypurinol: 18–30 hours (prolonged in renal impairment).
Clinical Note
moderateAllopurinol + Hydrochlorothiazide
"The risk of a hypersensitivity reaction to Hydrochlorothiazide is increased when it is combined with Allopurinol."
Clinical Note
moderateAllopurinol + Bendroflumethiazide
"The risk of a hypersensitivity reaction to Bendroflumethiazide is increased when it is combined with Allopurinol."
Clinical Note
moderateAllopurinol + Methyclothiazide
"The risk of a hypersensitivity reaction to Methyclothiazide is increased when it is combined with Allopurinol."
Clinical Note
moderateAllopurinol: 1-2 hours; oxypurinol: 18-30 hours (prolonged to 48-72 hours in renal impairment). Clinical context: oxypurinol half-life determines dosing interval; dose adjustment required for CrCl < 20 mL/min.
Renal: ~76% as unchanged drug and metabolites; oxypurinol (active metabolite) is primarily excreted renally. Biliary/fecal: minor, <5%.
Renal: allopurinol ~10% unchanged, oxypurinol ~70% unchanged; total renal elimination ~76% (allopurinol + oxypurinol); fecal/biliary: minor (~12-20% as allopurinol, ~3-5% as oxypurinol).
Category C
Category C
Xanthine Oxidase Inhibitor
Xanthine Oxidase Inhibitor
Allopurinol + Hydroflumethiazide
"The risk of a hypersensitivity reaction to Hydroflumethiazide is increased when it is combined with Allopurinol."